Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
11.95
-0.47 (-3.78%)
At close: Aug 1, 2025, 4:00 PM
12.00
+0.05 (0.42%)
After-hours: Aug 1, 2025, 4:10 PM EDT
AY Market Cap
Crescent Biopharma has a market cap or net worth of $166.71 million as of August 1, 2025.
Market Cap
166.71M
Enterprise Value
169.43M
1-Year Change
n/a
Ranking
Category
Stock Price
$11.95
Market Cap Chart
Since June 16, 2025, Crescent Biopharma's market cap has decreased from $219.43M to $166.71M, a decrease of -24.03%. That is a compound annual growth rate of -88.70%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Aug 1, 2025 | 166.71M | -3.38% |
Jul 31, 2025 | 172.55M | -1.43% |
Jul 30, 2025 | 175.05M | 2.44% |
Jul 29, 2025 | 170.88M | -7.17% |
Jul 28, 2025 | 184.08M | -0.30% |
Jul 25, 2025 | 184.63M | 2.07% |
Jul 24, 2025 | 180.88M | -1.21% |
Jul 23, 2025 | 183.10M | 1.07% |
Jul 22, 2025 | 181.16M | -1.21% |
Jul 21, 2025 | 183.38M | -1.05% |
Jul 18, 2025 | 185.33M | 2.46% |
Jul 17, 2025 | 180.88M | -0.91% |
Jul 16, 2025 | 182.55M | 11.88% |
Jul 15, 2025 | 163.17M | -8.24% |
Jul 14, 2025 | 177.82M | -1.23% |
Jul 11, 2025 | 180.05M | -4.00% |
Jul 10, 2025 | 187.55M | -8.72% |
Jul 9, 2025 | 205.47M | -1.99% |
Jul 8, 2025 | 209.64M | -1.31% |
Jul 7, 2025 | 212.42M | -3.78% |
Jul 3, 2025 | 220.75M | 2.22% |
Jul 2, 2025 | 215.96M | -3.75% |
Jul 1, 2025 | 224.36M | 0.06% |
Jun 30, 2025 | 224.23M | 1.51% |
Jun 27, 2025 | 220.89M | -5.92% |
Jun 26, 2025 | 234.78M | -6.11% |
Jun 25, 2025 | 250.07M | 19.48% |
Jun 24, 2025 | 209.29M | -1.54% |
Jun 23, 2025 | 212.56M | 2.00% |
Jun 20, 2025 | 208.39M | 2.60% |
Jun 18, 2025 | 203.11M | 10.17% |
Jun 17, 2025 | 184.35M | -15.99% |
Jun 16, 2025 | 219.43M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Eli Lilly and Company | 682.35B |
Johnson & Johnson | 402.82B |
AbbVie | 334.40B |
UnitedHealth Group | 241.34B |
AstraZeneca | 236.88B |
Novartis AG | 227.02B |
Abbott Laboratories | 223.66B |
Novo Nordisk | 221.96B |